Literature DB >> 30061050

Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective.

Shigeki Saito1, Joseph A Lasky2, Koichi Hagiwara3, Yasuhiro Kondoh4.   

Abstract

Epidemiologic data suggest that there are ethnic differences between Japanese and other populations with regard to the important clinical aspects of interstitial lung disease (ILD), such as the cause of death and prognostic factors in patients with idiopathic pulmonary fibrosis (IPF). Acute exacerbation (AE) of IPF may be more common in Japan than in the rest of the world, although this suggestion remains controversial. Moreover, AE of ILD induced by gefitinib may also be more common in Japan, indicating that Japanese patients have a genetic vulnerability or susceptibility to AE. Recent large-scale studies are starting to reveal ethnic differences in the genetics of ILD, including the prevalence of the genetic polymorphisms associated with the clinical course of ILD. We anticipate that ongoing and upcoming research regarding ethnic differences will continue to provide valuable insights into the pathogenesis and management of ILD.
Copyright © 2018 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute exacerbation; Ethnic differences; Idiopathic pulmonary fibrosis; Japanese

Mesh:

Substances:

Year:  2018        PMID: 30061050     DOI: 10.1016/j.resinv.2018.06.002

Source DB:  PubMed          Journal:  Respir Investig        ISSN: 2212-5345


  5 in total

1.  Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON.

Authors:  Jin Woo Song; Takashi Ogura; Yoshikazu Inoue; Zuojun Xu; Manuel Quaresma; Susanne Stowasser; Wibke Stansen; Bruno Crestani
Journal:  Respirology       Date:  2019-07-22       Impact factor: 6.424

2.  Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting.

Authors:  Eiko Iwasa; Yu Fujiyoshi; Yuki Kubota; Ryota Kimura; Rebecca E Chandler; Henric Taavola; G Niklas Norén; Rika Wakao
Journal:  Drug Saf       Date:  2020-11       Impact factor: 5.606

3.  Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis.

Authors:  Yasuhiro Kondoh; Takafumi Suda; Yoshie Hongo; Manami Yoshida; Shinzo Hiroi; Kosuke Iwasaki; Tomomi Takeshima; Sakae Homma
Journal:  Respir Res       Date:  2022-02-08

4.  Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance.

Authors:  Hisashi Uhara; Tetsuya Tsuchida; Yoshio Kiyohara; Ayumi Akamatsu; Takahiko Sakamoto; Naoya Yamazaki
Journal:  J Dermatol       Date:  2022-05-23       Impact factor: 3.468

5.  Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications.

Authors:  Bryan T Kelly; Viengneesee Thao; Timothy M Dempsey; Lindsey R Sangaralingham; Stephanie R Payne; Taylor T Teague; Teng Moua; Nilay D Shah; Andrew H Limper
Journal:  BMC Pulm Med       Date:  2021-07-17       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.